Senate Bill 876 creates new provisions in the Florida Insurance Code governing coverage for chimeric antigen receptor T-cell therapy, commonly known as CAR-T therapy. Beginning January 1, 2026, health insurers and health maintenance organizations that offer coverage for CAR-T therapy would be prohibited from refusing to contract with, or denying coverage for, administration of that therapy by a provider that is a certified healthcare facility under the applicable FDA product-license procedure and is already included in the plan’s provider network for some other service.
The bill applies separately to individual health insurance policies, group health insurance policies, and HMO contracts by creating new sections in chapters 627 and 641, Florida Statutes. In practical terms, it requires covered plans to allow access to qualifying CAR-T providers already in-network for other services, which could expand patient access to this specialized cancer treatment and limit insurers’ ability to narrow provider options for CAR-T administration.
Impact
The bill would amend Florida law by adding three new statutory sections—ss. 627.64198, 627.6614, and 641.31078, F.S.—to regulate how insurers and HMOs handle CAR-T therapy coverage. It does not mandate that plans cover CAR-T therapy if they otherwise do not, but if a plan does cover it, the plan could not exclude an otherwise in-network, FDA-certified facility from administering the therapy. The affected parties are health insurers, HMOs, certified healthcare facilities, and patients seeking CAR-T treatment, particularly those whose access depends on network participation.
Sentiment
No committee transcripts or recorded votes were provided, so there is no documented legislative debate or roll-call history to indicate support or opposition. Based on the bill text alone, the measure appears consumer- and access-oriented, with a focus on ensuring network access to a highly specialized therapy. The absence of recorded opposition or amendments in the provided materials means the overall sentiment cannot be assessed beyond the bill’s apparent intent.
Contention
The main potential point of contention is the bill’s restriction on insurer and HMO network discretion. Insurers may view the measure as limiting their ability to manage provider networks, negotiate contracts, or control costs for a high-cost specialty treatment. Supporters would likely emphasize patient access, continuity of care, and the importance of allowing treatment at certified facilities already recognized in a plan’s network for other services. No specific stakeholder positions were included in the provided record.